Europe Human Insulin Market Size, Share & Trends Analysis Report by Indication, Product Type (Pens, Syringes, and Others), Type of Insulin, Distribution Channel, Country and Growth Forecast, 2024-2031

The Europe Human Insulin Market is projected to witness market growth of 2.9% CAGR during the forecast period (2024-2031).

The Germany market dominated the Europe Human Insulin Market by country in 2023, and is projected to continue to be a dominant market till 2031; thereby, achieving a market value of $1.38 billion by 2031. The UK market is exhibiting a CAGR of 2% during 2024-2031. Additionally, the France market is anticipated to experience a CAGR of 4% during 2024-2031.



Advancements in insulin delivery systems have also contributed significantly to the growth of the insulin market. Insulin pens, for example, offer a more user-friendly and portable alternative to traditional vial-and-syringe methods, making insulin administration less intimidating and more accurate. Government initiatives and healthcare policies are crucial in shaping the human insulin market. Public health campaigns and educational initiatives also raise awareness about diabetes prevention and management, encouraging early diagnosis and proper treatment.

Rising awareness and education about diabetes management and the importance of insulin therapy have significantly improved diagnosis rates and treatment adherence. Public health campaigns, patient and provider education programs, initiatives in schools and workplaces, the efforts of non-profit organizations, and technological advancements have all contributed to this positive trend. These endeavors have improved health outcomes, enhanced the quality of care, and promoted the growth of the insulin market by ensuring that individuals are well-informed about diabetes and the critical role of insulin in its management.

France is experiencing a similar trend, with an aging population contributing to the increasing demand for insulin. According to the French National Institute of Statistics and Economic Studies (INSEE), in 2040, there would be 51 people aged 65 or over per 100 people aged 20 to 64, compared with 37 in 2021. The French Health Ministry estimates that approximately 3.5 million people in France have diabetes, and the prevalence is higher among older adults. Public health campaigns and initiatives by the French government aim to improve diabetes detection and management, ensuring patients receive appropriate care. The growing number of senior people in France, which has led to an increase in the number of people diagnosed with diabetes, is the primary factor driving the need for the insulin in the country. Hence, these elements will support the regional market's growth in the coming years.

Based on Indication, the market is segmented into Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes. Based on Product Type, the market is segmented into Pens, Syringes, and Others. Based on Type of Insulin, the market is segmented into Rapid-acting insulin, Short-acting insulin, Intermediate-acting insulin, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

List of Key Companies Profiled

• MannKind Corporation
• Lupin Limited
• Sanofi S.A.
• Novo Nordisk A/S
• Eli Lilly And Company
• Medtronic PLC
• Biocon Limited
• Tonghua Dongbao Pharmaceutical Co., Ltd.
• Pfizer, Inc.

Market Report Segmentation

By Indication

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

By Product Type

• Pens
• Syringes
• Others

By Type of Insulin

• Rapid-acting insulin
• Short-acting insulin
• Intermediate-acting insulin
• Others

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Providers

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe